For example, Chang employed matrix metalloproteinase-2 (MMP-2) responsive peptide (peptide E5)-modified engineered liposomes loaded with nintedanib (NIN) and colchicine (COL) that can firstly target endogenous monocyte-derived multipotent cells (MOMCs) and then be selectively delivered into IPF lungs (26). This evidence concerns the gene MMP2 and idiopathic interstitial pneumonia.